More than 200,000 women will be diagnosed with breast cancer this year alone.

While treatments have improved survival rates, one side effect is commonly referred to as
“chemobrain” or  “chemofog” within the cancer community.

Past findings suggested that one of the two most common treatments for early breast cancer, a class of drugs known as anthracyclines, is linked with this side effect.

But in a new analysis that looked at women nearly five years after treatment, those who got these drugs were no more likely to feel foggy, so these drugs don’t seem to be the culprits.

The findings appear in JAMA.

(ABC)